|
|
 | | | |
- close
- close
- close
- close
Biota Holdings (BTA-AU) |
QUOTE AND NEWS
Marketwire
May 11
Comment
MELBOURNE, AUSTRALIA -- (Marketwire) -- 05/11/12 -- Biota Holdings Limited (ASX: BTA) today announced that Daiichi Sankyo Co., Ltd. have provided written confirmation that Inavir® gross sales were JPY8.7bn and indicative royalties were $3.4 million
The Australian
Apr 27
Comment
IT was the deal that was supposed to bring the battling Biota to the attention of the all-important US market.
The Australian
Apr 23
Comment
FLU drug developer Biota's plan to merge with a US company and delist from the Australian Securities Exchange has gained support.
Globe Newswire
Apr 23
Comment
ROCKVILLE, Md., April 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced plans to merge with Biota Holdings Limited (ASX:BTA), a Melbourne, Australia company. The execution of the merger implementation agreement will
PR Newswire
Apr 17
Comment
ALBANY, N.Y., April 17, 2012 /PRNewswire/ -- AMRI (NYSE: AMRI), a leading global contract research and manufacturing organization, was selected by Biota Holdings Limited (ASX: BTA), a leading anti-infective drug development company based in
Sydney Morning Herald
Mar 28
Comment
More medical trials for anti-influenza technology that could treat cases of serious asthma.
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human Rhinovirus Infection (HRV)
Marketwire
Mar 28
Comment
MELBOURNE, AUSTRALIA -- (Marketwire) -- 03/28/12 -- Biota Holdings Limited (ASX: BTA) today announced that the Phase II clinical study of its oral antiviral BTA798 (vapendavir) for the treatment of naturally acquired human rhinovirus (HRV) infection
Marketwire
Feb 15
Comment
MELBOURNE, AUSTRALIA -- (Marketwire) -- 02/15/12 -- Biota Holdings Limited (ASX: BTA) today announced financial results for the first half of the Company's fiscal 2012. The Company reported a half-year loss of $11 million compared to a net loss of
The Australian
Aug 17
Comment
DRUG company Biota has reported a full-year net loss of $28.1 million, after a significant drop in royalties from its Relenza anti-flu drug.
Marketwire
Aug 17
Comment
MELBOURNE, AUSTRALIA -- (Marketwire) -- 08/17/11 -- Biota Holdings Limited (ASX: BTA) Highlights BARDA awarded a major contract to Biota for the advanced development of laninamivir in the US. The US$231 million contract is in excess of the Company's
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| |||||||
